Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$57.89 - $64.73 $278,393 - $311,286
4,809 New
4,809 $279,000
Q2 2023

Aug 04, 2023

SELL
$63.71 - $70.74 $796,757 - $884,674
-12,506 Closed
0 $457,000
Q1 2023

May 15, 2023

SELL
$65.71 - $74.53 $54,867 - $62,232
-835 Reduced 6.26%
12,506 $811,000
Q4 2022

Feb 03, 2023

SELL
$68.48 - $81.09 $322,609 - $382,014
-4,711 Reduced 26.1%
13,341 $960,000
Q3 2022

Oct 21, 2022

SELL
$0.13 - $76.84 $139 - $82,449
-1,073 Reduced 5.61%
18,052 $1.28 Million
Q2 2022

Jul 28, 2022

SELL
$72.62 - $79.98 $61,872 - $68,142
-852 Reduced 4.26%
19,125 $1.47 Million
Q1 2022

May 12, 2022

SELL
$61.48 - $73.72 $94,740 - $113,602
-1,541 Reduced 7.16%
19,977 $1.46 Million
Q4 2021

Feb 07, 2022

SELL
$53.63 - $62.52 $329,341 - $383,935
-6,141 Reduced 22.2%
21,518 $1.34 Million
Q3 2021

Oct 06, 2021

SELL
$59.17 - $69.31 $1.01 Million - $1.18 Million
-17,036 Reduced 38.12%
27,659 $1.64 Million
Q2 2021

Jul 06, 2021

BUY
$61.91 - $67.42 $1.03 Million - $1.13 Million
16,692 Added 59.61%
44,695 $2.99 Million
Q1 2021

Apr 07, 2021

BUY
$59.34 - $66.74 $566,815 - $637,500
9,552 Added 51.77%
28,003 $1.77 Million
Q4 2020

Feb 01, 2021

SELL
$57.74 - $65.43 $17,495 - $19,825
-303 Reduced 1.62%
18,451 $1.15 Million
Q3 2020

Oct 15, 2020

BUY
$57.43 - $63.64 $60,358 - $66,885
1,051 Added 5.94%
18,754 $1.13 Million
Q2 2020

Jul 22, 2020

BUY
$54.82 - $64.09 $307,101 - $359,032
5,602 Added 46.29%
17,703 $1.04 Million
Q1 2020

May 04, 2020

SELL
$46.4 - $67.43 $2,273 - $3,304
-49 Reduced 0.4%
12,101 $675,000
Q4 2019

Feb 04, 2020

BUY
$49.21 - $64.19 $597,901 - $779,908
12,150 New
12,150 $780,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Hodges Capital Management Inc. Portfolio

Follow Hodges Capital Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hodges Capital Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hodges Capital Management Inc. with notifications on news.